造血干细胞输注联合增加化疗剂量治疗卵巢癌的效果  

Application Efficacy Research of Hematopoietic Stem Cell Infusion in and Increasing Doses of Chemotherapy Treatment Offor Ovarian Cancer

作　　者：孙波 曹舫 姚安梅 

机构地区：[1]陕西省肿瘤医院,710061

出　　处：《实用癌症杂志》2016年第3期434-436,共3页The Practical Journal of Cancer

摘　　要：目的造血干细胞输注在增加化疗剂量治疗卵巢癌中的应用效果。方法选取从2011年3月到2013年3月收治的卵巢癌患者共100例。随机将患者分为观察组和对照组,其中观察组患者采用造血干细胞联合大剂量化疗;对照组患者则采用常规的化疗方案。结果观察组CR 30例,对照组为14例,2组差异有统计学意义(P<0.05)。观察组治疗有效率为98.0%,对照组为78.0%,差异有统计学意义(P<0.05)。对照组不良反应发生率高于观察组,差异有统计学意义(P<0.05)。结论采用造血干细胞输注联合增加化疗剂量治疗卵巢癌能够取得满意的治疗效果,但增加化疗剂量也会提高化疗的毒副作用,在治疗过程中需密切关注患者身体反应。Objective To explore the effecticacy of hematopoietic stem cell infusion inand increasing doses of chemotherapy treatment of for ovarian cancer. Methods From March 2011 to March 2013 100 cases of patients with ovarian cancer were randomly divided into two groups. The control group was with received the conventional chemotherapy regimens, the observation group withreceived hematopoietic stem cells in combination withand large dose of chemotherapy. Results CR cases of in the observation group was 62.0% , and CR in the control group was 28.0% , and the difference between the two groups was statistically significant （P 〈 0. 05 ）. The effective rate of the treatment group was 98.0% , and of the control group was 78.0% , and the difference between the two groups was statistically significant （ P 〈 0. 05 ）. The adverse reactions rate of the control group was higher than that of the observation group, and the difference was statistically significant （ P 〈 0. 05 ）. Conclusion Hematopoietic stem cell infusion jointand increased doses of chemotherapy infor ovarian cancer treatment can obtain satisfactory therapeutic effect, but increase the dose of chemotherapy will improve the side effects of chemotherapy. Physical reactions of patients should belt need to pay close attention considered in the process of treatment of patients with physical reactions.

关 键 词：造血干细胞输注 增加化疗剂量 卵巢癌 

分 类 号：R737.31[医药卫生—肿瘤]